Tissue | Expression Dynamics | Abbreviation |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00315897 | Lung | IAC | cell-substrate adhesion | 85/2061 | 363/18723 | 8.57e-12 | 4.27e-09 | 85 |
GO:00480416 | Lung | IAC | focal adhesion assembly | 34/2061 | 87/18723 | 9.46e-12 | 4.27e-09 | 34 |
GO:00518937 | Lung | IAC | regulation of focal adhesion assembly | 29/2061 | 66/18723 | 1.01e-11 | 4.27e-09 | 29 |
GO:00901097 | Lung | IAC | regulation of cell-substrate junction assembly | 29/2061 | 66/18723 | 1.01e-11 | 4.27e-09 | 29 |
GO:01501157 | Lung | IAC | cell-substrate junction organization | 36/2061 | 101/18723 | 5.37e-11 | 1.52e-08 | 36 |
GO:00226048 | Lung | IAC | regulation of cell morphogenesis | 74/2061 | 309/18723 | 6.31e-11 | 1.70e-08 | 74 |
GO:01501167 | Lung | IAC | regulation of cell-substrate junction organization | 29/2061 | 71/18723 | 8.86e-11 | 2.29e-08 | 29 |
GO:00019527 | Lung | IAC | regulation of cell-matrix adhesion | 40/2061 | 128/18723 | 4.69e-10 | 9.93e-08 | 40 |
GO:00108108 | Lung | IAC | regulation of cell-substrate adhesion | 57/2061 | 221/18723 | 5.09e-10 | 1.04e-07 | 57 |
GO:00343297 | Lung | IAC | cell junction assembly | 86/2061 | 420/18723 | 7.98e-09 | 1.10e-06 | 86 |
GO:00715594 | Lung | IAC | response to transforming growth factor beta | 60/2061 | 256/18723 | 9.50e-09 | 1.25e-06 | 60 |
GO:00457858 | Lung | IAC | positive regulation of cell adhesion | 87/2061 | 437/18723 | 2.59e-08 | 3.13e-06 | 87 |
GO:00715604 | Lung | IAC | cellular response to transforming growth factor beta stimulus | 57/2061 | 250/18723 | 6.17e-08 | 6.54e-06 | 57 |
GO:19018885 | Lung | IAC | regulation of cell junction assembly | 46/2061 | 204/18723 | 1.56e-06 | 7.76e-05 | 46 |
GO:00430876 | Lung | IAC | regulation of GTPase activity | 67/2061 | 348/18723 | 3.43e-06 | 1.44e-04 | 67 |
GO:00072294 | Lung | IAC | integrin-mediated signaling pathway | 28/2061 | 107/18723 | 9.18e-06 | 3.06e-04 | 28 |
GO:00452168 | Lung | IAC | cell-cell junction organization | 43/2061 | 200/18723 | 1.21e-05 | 3.64e-04 | 43 |
GO:00108118 | Lung | IAC | positive regulation of cell-substrate adhesion | 29/2061 | 123/18723 | 5.35e-05 | 1.21e-03 | 29 |
GO:00435475 | Lung | IAC | positive regulation of GTPase activity | 48/2061 | 255/18723 | 1.40e-04 | 2.60e-03 | 48 |
GO:00019546 | Lung | IAC | positive regulation of cell-matrix adhesion | 16/2061 | 58/18723 | 3.85e-04 | 5.87e-03 | 16 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LIMS1 | SNV | Missense_Mutation | novel | c.61N>T | p.Arg21Cys | p.R21C | P48059 | protein_coding | deleterious_low_confidence(0.01) | benign(0.348) | TCGA-AC-A2FE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
LIMS1 | SNV | Missense_Mutation | novel | c.473N>T | p.Arg158Leu | p.R158L | P48059 | protein_coding | tolerated(0.39) | benign(0.015) | TCGA-BH-A1FC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LIMS1 | SNV | Missense_Mutation | | c.1127G>T | p.Arg376Ile | p.R376I | P48059 | protein_coding | tolerated(0.06) | probably_damaging(0.991) | TCGA-D8-A1X6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
LIMS1 | SNV | Missense_Mutation | rs149119038 | c.67N>A | p.Asp23Asn | p.D23N | P48059 | protein_coding | tolerated_low_confidence(0.48) | benign(0) | TCGA-EA-A3QE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
LIMS1 | SNV | Missense_Mutation | | c.247N>A | p.Glu83Lys | p.E83K | P48059 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LIMS1 | SNV | Missense_Mutation | | c.874C>T | p.Arg292Cys | p.R292C | P48059 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
LIMS1 | SNV | Missense_Mutation | rs200004487 | c.220N>T | p.Arg74Cys | p.R74C | P48059 | protein_coding | deleterious(0.02) | probably_damaging(0.953) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
LIMS1 | insertion | Nonsense_Mutation | novel | c.892_893insTTTGAGACA | p.Gly298delinsValTerAspSer | p.G298delinsV*DS | P48059 | protein_coding | | | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LIMS1 | SNV | Missense_Mutation | novel | c.556N>T | p.Arg186Cys | p.R186C | P48059 | protein_coding | deleterious(0.01) | possibly_damaging(0.901) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LIMS1 | SNV | Missense_Mutation | rs377342624 | c.794N>A | p.Arg265His | p.R265H | P48059 | protein_coding | deleterious(0.04) | probably_damaging(0.918) | TCGA-AJ-A3OK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |